Get Premium to unlock powerful stock data
NYSE:LLY (USA)  
Eli Lilly and Co logo

Eli Lilly and Co

$ 328.20 +2.58 (+0.79%) 10:10 AM EST
On watch
P/E:
49.17
P/B:
33.36
Market Cap:
$ 311.18B
Enterprise V:
$ 323.33B
Volume:
534.53K
Avg Vol (2M):
3.24M
Also Trade In:
Volume:
534.53K
Market Cap $:
311.18B
PE Ratio:
49.17
Avg Vol (2-Month):
3.24M
Enterprise Value $:
323.33B
PB Ratio:
33.36
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Description
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Financials (Next Earnings Date:2022-08-04)

LLY's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NYSE:LLY

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 29,322.8
EPS (TTM) ($) 6.66
Beta 0.41
Volatility % 30.18
14-Day RSI 65.96
14-Day ATR ($) 9.466039
20-Day SMA ($) 304.5575
12-1 Month Momentum % 31.33
52-Week Range ($) 220.2 - 328.15
Shares Outstanding (Mil) 950.16

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Eli Lilly and Co Filings

Document Form Filing Date
No Filing Data

Headlines

See More